HIKAL
|
The Current P/E Ratio of HIKAL is -170.20.
| Share Price | ₹179.5 | Apr 10,2026 |
| Market Cap | ₹2,212.6 Cr | |
| Earnings-TTM | ₹-13.0 Cr | TTM-Consolidated Results |
| Price/Earnings | -170.20x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of HIKAL
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹2,212.6 Cr] as on Apr 10,2026
(/) Earnings [ ₹-13.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ -170.20x ]
Thus, for HIKAL , the investors are currently willing to pay -170.20 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of HIKAL !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of HIKAL over the last five years.
Historical PE (Price/Earnings) ratio chart of HIKAL
PE Ratio Performance Analysis for HIKAL
- HIKAL 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 37.99x.
- HIKAL 's operated at median p/e ratio of 44.34x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, HIKAL 's p/e ratio peaked in Mar2025 at 54.42x.
- HIKAL 's p/e ratio hit its five-year low in Mar2021 of 13.29x.
How does HIKAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| HIKAL | -13.00 | -170.20 | 2,212.6 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 36.09 | 397,018.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 65.53 | 162,454.0 |
| CIPLA LTD | 4,544.70 | 21.86 | 99,325.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 61.93 | 140,702.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 18.67 | 102,830.0 |
| MANKIND PHARMA LTD | 1,796.65 | 47.76 | 85,816.7 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.67 | 92,115.7 |
| LUPIN LTD | 4,669.18 | 22.84 | 106,646.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 22.32 | 78,408.2 |
| ABBOTT INDIA LTD | 1,524.13 | 35.93 | 54,759.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs HIKAL 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -170.20x |
| Max industry PE | 65.53x |
| Median industry PE | 22.84x |
| Average industry PE | 16.49x |
You may also like the below Video Courses